Roles of Rho/ROCK in Cancer Signaling

  • Yesim Gökmen-PolarEmail author


The members of Rho/ROCK signaling pathway are well-established regulators of actin cytoskeleton and dynamics. Accumulating evidence demonstrates their key roles in other biological processes including polarity, motility, invasion, cell cycle progression, and survival. Aberrant Rho/ROCK signaling have been implicated in both preclinical and clinical samples of several cancers. Mutations of Rho GTPases and ROCK isoforms (ROCK1 and ROCK2) have been reported in tumor samples. In addition, their elevated expression levels have been associated with poor outcome in those tumors. Therefore, Rho/ROCK family genes serve as promising candidates for therapeutic targeting in several cancers. This review focuses on the recent progress in therapeutic targeting of the Rho/ROCK signaling pathway in cancer. In particular, we focus on the potential utility of inhibitors of ROCK, downstream effectors of Rho GTPases, as they have been considered more specific to inhibit Rho/ROCK activity. Although no effective drugs targeting Rho/ROCK activity are available for the clinical management of cancer, studies using drugs that pharmacologically inhibit ROCK isoforms suggest a promising future. AT13148, an inhibitor of members of AGC kinase family including ROCK1 and ROCK2, is in phase 1 clinical trial initiated in 2012 for the treatment of advanced solid tumors ( identifier NCT01585701). A deeper understanding of this pathway using isoform-specific inhibitors of Rho kinases (ROCK1 and ROCK2) may add new treatment options for future precision cancer therapy improving the clinical utility of this pathway.


Rho GTPases ROCK ROCK1 ROCK2 Cancer ROCK inhibitors 


Conflict of Interest

The author has no conflict of interest.


  1. 1.
    Porter AP, Papaioannou A, Malliri A. Deregulation of Rho GTPases in cancer. Small GTPases. 2016;7(3):123–38.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4(5):387–98.CrossRefPubMedGoogle Scholar
  4. 4.
    Wei L, et al. Novel insights into the roles of Rho kinase in cancer. Arch Immunol Ther Exp. 2016;64(4):259–78.CrossRefGoogle Scholar
  5. 5.
    Morgan-Fisher M, Wewer UM, Yoneda A. Regulation of ROCK activity in cancer. J Histochem Cytochem. 2013;61(3):185–98.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420(6916):629–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Kale VP, et al. The regulatory roles of ROCK and MRCK kinases in the plasticity of cancer cell migration. Cancer Lett. 2015;361(2):185–96.CrossRefPubMedGoogle Scholar
  8. 8.
    Amin E, et al. Rho-kinase: regulation, (dys)function, and inhibition. Biol Chem. 2013;394(11):1399–410.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20(2):242–8.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci. 2010;67(2):171–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Ying H, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 2006;5(9):2158–64.CrossRefPubMedGoogle Scholar
  12. 12.
    Nakajima M, et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol. 2003;459(2–3):113–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Teiti I, et al. In vivo effects in melanoma of ROCK inhibition-induced FasL overexpression. Front Oncol. 2015;5:156.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Patel RA, et al. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012;72(19):5025–34.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Fagan-Solis KD, et al. The RhoA pathway mediates MMP-2 and MMP-9-independent invasive behavior in a triple-negative breast cancer cell line. J Cell Biochem. 2013;114(6):1385–94.CrossRefPubMedGoogle Scholar
  16. 16.
    Tsai CC, et al. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. Biochem Pharmacol. 2011;81(7):856–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Patel RA, et al. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene. 2014;33(5):550–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Vigil D, et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012;72(20):5338–47.CrossRefPubMedGoogle Scholar
  19. 19.
    Xi Y, et al. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2016;478(1):330–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Sadok A, et al. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res. 2015;75(11):2272–84.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineIndiana University School of MedicineIndianapolisUSA

Personalised recommendations